FGF-401
Modify Date: 2024-01-02 14:44:29
FGF-401 structure
|
Common Name | FGF-401 | ||
|---|---|---|---|---|
| CAS Number | 1708971-55-4 | Molecular Weight | 506.557 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 852.1±65.0 °C at 760 mmHg | |
| Molecular Formula | C25H30N8O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 469.1±34.3 °C | |
Use of FGF-401FGF-401 is an inhibitor of FGFR4 extracted from patent WO2015059668A1, compound example 83; has an IC50 of 1.9 nM. |
| Name | FGF-401 |
|---|---|
| Synonym | More Synonyms |
| Description | FGF-401 is an inhibitor of FGFR4 extracted from patent WO2015059668A1, compound example 83; has an IC50 of 1.9 nM. |
|---|---|
| Related Catalog | |
| Target |
FGFR4:1.9 nM (IC50) |
| In Vivo | FGF-401 is a FGFR4 inhibitor developed for the treatment of solid tumor. FGF-401 is a FGFR4 inhibitor in phase I/II clinical studies for the treatment of positive FGFR4 and KLB expresion solid tumors and hepatocellular carcinoma[1]. |
| References |
[1]. WO2015059668A1 |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 852.1±65.0 °C at 760 mmHg |
| Molecular Formula | C25H30N8O4 |
| Molecular Weight | 506.557 |
| Flash Point | 469.1±34.3 °C |
| Exact Mass | 506.239014 |
| LogP | -0.15 |
| Vapour Pressure | 0.0±3.2 mmHg at 25°C |
| Index of Refraction | 1.654 |
| Storage condition | -20℃ |
| 1,8-Naphthyridine-1(2H)-carboxamide, N-[5-cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl]-7-formyl-3,4-dihydro-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]- |
| N-{5-Cyano-4-[(2-methoxyethyl)amino]-2-pyridinyl}-7-formyl-6-[(4-methyl-2-oxo-1-piperazinyl)methyl]-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
| FGF401 |